Article

Loteprednol, azelastine provide potent arsenal for acute, chronic allergic conjunctivitis

Loteprednol etabonate 0.2% (Alrex, Bausch & Lomb) and azelastine hydrochloride 0.05% (Optivar, Muro) are both valuable options for the management of seasonal and perennial allergic conjunctivitis, said Charles Slonim, MD.

Related Videos
J. Peter Campbell, MD, MPH
Expanding accessibility of vision correction with spectacles for children with cranial abnormalities
Elkin: Talking about the importance of pediatric eye health and safety
Identifying 3 barriers keeping families from accessing cataract treatment for their children in India
Edward Manche, MD
Related Content
Alkeus Pharmaceuticals receives FDA Rare Pediatric Disease and Fast Track designations for gildeuretinol as treatment for Stargardt disease
November 18th 2024

Alkeus Pharmaceuticals receives FDA Rare Pediatric Disease and Fast Track designations for gildeuretinol as treatment for Stargardt disease

ROP: Treating and preventing blindness in preterm babies
October 18th 2021

ROP: Treating and preventing blindness in preterm babies

Study explores the true costs of treating pediatric cataracts
November 12th 2024

Study explores the true costs of treating pediatric cataracts

Managing a changing landscape of IRD pediatric cases
May 10th 2021

Managing a changing landscape of IRD pediatric cases

Cerebral visual impairment: A growing concern in pediatric vision loss
October 30th 2024

Cerebral visual impairment: A growing concern in pediatric vision loss

Factors affecting ROP development in the 8 weeks following birth
October 24th 2024

Factors affecting ROP development in the 8 weeks following birth

© 2024 MJH Life Sciences

All rights reserved.